Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novartis Ag (NVS)

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 216,260,160
  • Shares Outstanding, K 2,294,294
  • Annual Sales, $ 53,166 M
  • Annual Income, $ 12,611 M
  • 60-Month Beta 0.59
  • Price/Sales 4.17
  • Price/Cash Flow 11.57
  • Price/Book 4.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 1.26
  • Number of Estimates 1
  • High Estimate 1.26
  • Low Estimate 1.26
  • Prior Year 1.31
  • Growth Rate Est. (year over year) -3.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
88.03 +6.28%
on 07/12/19
95.00 -1.52%
on 07/18/19
+1.65 (+1.80%)
since 06/19/19
3-Month
74.97 +24.80%
on 04/22/19
95.00 -1.52%
on 07/18/19
+17.15 (+22.44%)
since 04/18/19
52-Week
71.33 +31.17%
on 08/15/18
95.00 -1.52%
on 07/18/19
+22.49 (+31.64%)
since 07/19/18

Most Recent Stories

More News
Top Research Reports for Abbott, Netflix & Philip Morris

Top Research Reports for Abbott, Netflix & Philip Morris

NFLX : 315.10 (-3.11%)
ABT : 87.49 (-0.31%)
UTX : 132.39 (+0.83%)
NVS : 93.56 (-0.74%)
PM : 88.73 (+1.16%)
BMY : 43.33 (-1.63%)
Anti-Epileptic Drugs For Pediatrics Market: Newer Drug Therapies With Symptom Specific Indications

Anti-epileptics drugs for pediatrics treatment are expected to experience visible shifts in terms of demand and adoption owing to factors such as rise in global prevalence of epilepsy, increasing healthcare...

VRX.TO : 30.80 (-3.33%)
NVS : 93.56 (-0.74%)
GSK : 40.96 (-1.09%)
PFE : 42.77 (-0.67%)
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus

J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.

AZN : 40.12 (-1.50%)
MRK : 81.39 (-1.57%)
JNJ : 130.31 (-1.33%)
AGN : 163.16 (+0.68%)
NVS : 93.56 (-0.74%)
ABBV : 68.54 (+0.42%)
GSK : 40.96 (-1.09%)
Keloid Treatment Market 2019|Top Key Players Analysis, Trends, Global Size Forecast To 2024

The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Pacific...

VRX.TO : 30.80 (-3.33%)
GALE : 0.26 (-7.14%)
AVMXY : 6.0800 (+2.18%)
NVS : 93.56 (-0.74%)
SNOA : 6.18 (-0.96%)
GSK : 40.96 (-1.09%)
BMY : 43.33 (-1.63%)
PRGO : 51.56 (+0.29%)
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus,...

NVS : 93.56 (-0.74%)
GILD : 65.04 (-3.23%)
Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma

STOCKHOLM - July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made...

NVS : 93.56 (-0.74%)
Sunstone Life Science Ventures Joins Forendo Pharma Investor Syndicate

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women's health, today announces that Sunstone Life Science Ventures has made a EUR 5 million investment in Forendo....

NVS : 93.56 (-0.74%)
Medicxi Closes a New EUR400m Fund (Medicxi III) to Power the Next Wave of Biopharma Entrepreneurs and Drug Hunters

Leading European life sciences investment firm Medicxi today announces the closing of Medicxi III, a new EUR400 million fund. This brings the total amount raised by Medicxi in the last three years to over...

ADPT : 38.53 (+1.37%)
NVS : 93.56 (-0.74%)
NERV : 6.53 (+0.62%)
Netflix, United Rentals fall while Union Pacific, eBay rise

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Thursday:

ASH : 76.11 (+0.81%)
UNP : 175.30 (+0.60%)
NVS : 93.56 (-0.74%)
URI : 118.98 (-1.76%)
PM : 88.73 (+1.16%)
Is a Beat in Store for Glaxo (GSK) This Earnings Season?

Glaxo's (GSK) Vaccines segment is likely to witness sales growth in the second quarter.

MRK : 81.39 (-1.57%)
AGN : 163.16 (+0.68%)
NVS : 93.56 (-0.74%)
GSK : 40.96 (-1.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

See More Share

Trade NVS with:

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Key Turning Points

2nd Resistance Point 95.43
1st Resistance Point 94.50
Last Price 93.56
1st Support Level 93.00
2nd Support Level 92.43

See More

52-Week High 95.00
Last Price 93.56
Fibonacci 61.8% 85.96
Fibonacci 50% 83.16
Fibonacci 38.2% 80.37
52-Week Low 71.33

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar